Literature DB >> 6251250

State of hepatitis B viral DNA in a human hepatoma cell line.

P L Marion, F H Salazar, J J Alexander, W S Robinson.   

Abstract

PLC/PRF/5, a tissue culture cell line isolated from a human hepatocellular carcinoma and producing hepatitis B surface antigen, was studied for the presence of hepatitis B virus (HBV)-specific DNA and RNA. PLC/PRF/5 cell DNA accelerated the rate of reassociation of HBV [32P]DNA, and quantitative experiments indicated that the cells contained approximately four copies of viral DNA per haploid, mammalian cell DNA equivalent. PLC/PRF/5 DNA accelerated the rate of reassociation of all individual restriction endonucleases HincII and HaeIII fragments of HBV [32P]DNA, indicating that DNA from all regions of the viral genome is present in the cells. This suggests that these cells contain at least most, and possibly all, of the viral genome. Digestion of PLC/PRF/5 cell DNA with restriction endonuclease HindIII (an enzyme found not to cleave the DNA of any HBV isolate so far examined) yielded only three fragments, all larger than virion DNA, which contained HBV DNA base sequences, suggesting that HBV DNA is integrated in high-molecular-weight DNA at three different sites in these cells and that there is no viral DNA in an episomal form. PLC/PRF/5 cell [32P]RNA was found to hybridize with all restriction fragments of HBV DNA adequately tested, indicating that at least most, and possibly all, of the viral DNA in these cells is transcribed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6251250      PMCID: PMC288606     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles.

Authors:  J Summers; A O'Connell; I Millman
Journal:  Proc Natl Acad Sci U S A       Date:  1975-11       Impact factor: 11.205

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  Virus-like particles in serum of patients with Australia-antigen-associated hepatitis.

Authors:  D S Dane; C H Cameron; M Briggs
Journal:  Lancet       Date:  1970-04-04       Impact factor: 79.321

4.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

5.  DNA of a human hepatitis B virus candidate.

Authors:  W S Robinson; D A Clayton; R L Greenman
Journal:  J Virol       Date:  1974-08       Impact factor: 5.103

6.  Australia antigen subtypes. Discussion.

Authors:  J P Soulier
Journal:  Bibl Haematol       Date:  1976

7.  Further studies on a "new" human isoprecipitin system (Australia antigen).

Authors:  H J Alter; B S Blumberg
Journal:  Blood       Date:  1966-03       Impact factor: 22.113

8.  DNA synthesized in the hepatitis B Dane particle DNA polymerase reaction.

Authors:  L I Lutwick; W S Robinson
Journal:  J Virol       Date:  1977-01       Impact factor: 5.103

9.  DNA polymerase associated with human hepatitis B antigen.

Authors:  P M Kaplan; R L Greenman; J L Gerin; R H Purcell; W S Robinson
Journal:  J Virol       Date:  1973-11       Impact factor: 5.103

10.  Hepatitis B surface antigen produced by a human hepatoma cell line.

Authors:  G M MacNab; J J Alexander; G Lecatsas; E M Bey; J M Urbanowicz
Journal:  Br J Cancer       Date:  1976-11       Impact factor: 7.640

View more
  32 in total

1.  Rearrangement of a common cellular DNA domain on chromosome 4 in human primary liver tumors.

Authors:  C Pasquinelli; F Garreau; L Bougueleret; E Cariani; K H Grzeschik; V Thiers; O Croissant; M Hadchouel; P Tiollais; C Bréchot
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

2.  Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines.

Authors:  C R Carlin; D Simon; J Mattison; B B Knowles
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

Review 3.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

4.  Activities of arabinosyladenine monophosphate and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against ground squirrel hepatitis virus in vivo as determined by reduction in serum virion-associated DNA polymerase.

Authors:  D F Smee; S S Knight; A E Duke; W S Robinson; T R Matthews; P L Marion
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

5.  Detection of hepatitis B virus DNA in hepatocellular carcinoma.

Authors:  J Y Chen; T J Harrison; C S Lee; D S Chen; A J Zuckerman
Journal:  Br J Exp Pathol       Date:  1986-04

Review 6.  Mobile elements and viral integrations prompt considerations for bacterial DNA integration as a novel carcinogen.

Authors:  Kelly M Robinson; Julie C Dunning Hotopp
Journal:  Cancer Lett       Date:  2014-06-21       Impact factor: 8.679

7.  PLC/PRF/5 (Alexander) hepatoma cell line: further characterization and studies of infectivity.

Authors:  R J Daemer; S M Feinstone; J J Alexander; J G Tully; W T London; D C Wong; R H Purcell
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

8.  Detection of hepatitis B virus DNA in hepatocytes, bile duct epithelium, and vascular elements by in situ hybridization.

Authors:  H E Blum; L Stowring; A Figus; C K Montgomery; A T Haase; G N Vyas
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

9.  Establishment and characterization of a new human hepatocellular carcinoma cell line.

Authors:  L He; K J Isselbacher; J R Wands; H M Goodman; C Shih; A Quaroni
Journal:  In Vitro       Date:  1984-06

10.  Cloning and analysis of integrated hepatitis virus sequences from a human hepatoma cell line.

Authors:  Y Shaul; M Ziemer; P D Garcia; R Crawford; H Hsu; P Valenzuela; W J Rutter
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.